keyword
MENU ▼
Read by QxMD icon Read
search

Dry powder inhaler

keyword
https://www.readbyqxmd.com/read/29355645/errors-in-the-use-of-inhalers-by-healthcare-professionals-a-systematic-review
#1
Vicente Plaza, Jordi Giner, Gustavo J Rodrigo, Myrna B Dolovich, Joaquin Sanchis
BACKGROUND: Inefficient inhaler technique (IT) compromises the optimal delivery of medication. However, the IT knowledge of health care professionals (HCP) has received scant attention. OBJECTIVE: To perform a systematic review of published reports assessing the IT proficiency of HCPs in using pressurized metered dose (pMDI) and dry powder (DPI) inhalers. METHODS: Studies published between 1975 and 2014 that directly assessed the IT skills of HCPs were selected according to pre-defined selection criteria...
January 17, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29346430/estimation-of-inhalation-flow-profile-using-audio-based-methods-to-assess-inhaler-medication-adherence
#2
Terence E Taylor, Helena Lacalle Muls, Richard W Costello, Richard B Reilly
Asthma and chronic obstructive pulmonary disease (COPD) patients are required to inhale forcefully and deeply to receive medication when using a dry powder inhaler (DPI). There is a clinical need to objectively monitor the inhalation flow profile of DPIs in order to remotely monitor patient inhalation technique. Audio-based methods have been previously employed to accurately estimate flow parameters such as the peak inspiratory flow rate of inhalations, however, these methods required multiple calibration inhalation audio recordings...
2018: PloS One
https://www.readbyqxmd.com/read/29341919/performance-of-an-acoustically-mixed-pharmaceutical-dry-powder-delivered-from-a-novel-inhaler
#3
Ryoma Tanaka, Naoyuki Takahashi, Yasuaki Nakamura, Yusuke Hattori, Kazuhide Ashizawa, Makoto Otsuka
No abstract text is available yet for this article.
January 13, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29317923/identification-of-inhaler-technique-errors-with-a-routine-procedure-in-portuguese-community-pharmacy
#4
M Margarida Castel-Branco, Ana Fontes, Isabel V Figueiredo
Background: A correct selection of drugs prescribed, but also the choice of the appropriate inhaler device, is crucial for the control of respiratory diseases. Objective: To evaluate the inhaler technique and identify potential errors of patients when treated with inhalers by testing a routinary procedure to be implemented in any community pharmacy. Methods: Adults with asthma/COPD and under inhalation therapy were invited to demonstrate how they use their inhalers...
October 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/29289516/probing-the-particulate-microstructure-of-the-aerodynamic-particle-size-distribution-of-dry-powder-inhaler-combination-products
#5
M W Jetzer, B D Morrical, M Schneider, S Edge, G Imanidis
The in vitro aerosol performance of two combination dry powder inhaler (DPI) products, Foster® NEXThaler® and Seretide® Diskus® were investigated with single particle aerosol mass spectrometry (SPAMS). The in-vitro pharmaceutical performance is markedly different for both inhalers. Foster® NEXThaler® generates a higher fine particle fraction (FPF <5 μm) and a much higher relative extra fine particle fraction (eFPF <2 μm). In terms of the composition of the aerodynamic particle size distribution (APSD), it could be verified with SPAMS that overall Foster® NEXThaler® emits a significantly higher number of fine and extra fine particles with a median aerodynamic diameter (MAD) of 2...
December 28, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29277688/ability-of-using-different-dry-powder-inhalers-during-copd-exacerbations
#6
Andriana I Papaioannou, Yiolanda Herodotou, Ioannis Tomos, Vasiliki Apollonatou, Galateia Verykokou, Evgenia Papathanasiou, Effrosyni D Manali, Stelios Loukides, Spyros A Papiris
BACKGROUND: Guidelines suggest that patients hospitalized for acute COPD exacerbations (AECOPD) are treated with short acting bronchodilators. Long acting bronchodilators, offer longer symptom relief but since they are usually administered via Dry Powder Inhalers (DPIs) it is considered that during AECOPD patients would not be able to achieve appropriate inspiratory flow (IF) to receive appropriate drug doses. The aim of the present study was to evaluate whether patients admitted to the hospital for AECOPD, are able to achieve the necessary IF using different DPIs...
December 19, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29277683/new-aerosol-formulation-to-control-ciprofloxacin-pulmonary-concentration
#7
Barbara Lamy, Frederic Tewes, Dolores Remedios Serrano, Isabelle Lamarche, Patrice Gobin, William Couet, Anne Marie Healy, Sandrine Marchand
Ciprofloxacin (CIP) apparent permeability across a pulmonary epithelium model can be controlled by the affinity of its complex with a metal cation. The higher the complex affinity, the larger is the reduction in CIP apparent permeability. The aim of this study was to evaluate if the control of the CIP apparent permeability observed in vitro could be transposed in vivo to control the CIP lung-to-blood absorption rate and CIP concentrations in the lung epithelial lining fluid (ELF) after intratracheal (IT) administration...
December 22, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29261454/development-of-an-inline-dry-power-inhaler-that-requires-low-air-volume
#8
Dale Farkas, Michael Hindle, P Worth Longest
BACKGROUND: Inline dry powder inhalers (DPIs) are actuated by an external air source and have distinct advantages for delivering aerosols to infants and children, and to individuals with compromised lung function or who require ventilator support. However, current inline DPIs either perform poorly, are difficult to operate, and/or require large volumes (∼1 L) of air. The objective of this study was to develop and characterize a new inline DPI for aerosolizing spray-dried formulations with powder masses of 10 mg and higher using a dispersion air volume of 10 mL per actuation that is easy to load (capsule-based) and operate...
December 20, 2017: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/29260462/agglomerated-novel-spray-dried-lactose-leucine-tailored-as-a-carrier-to-enhance-the-aerosolization-performance-of-salbutamol-sulfate-from-dpi-formulations
#9
Carlos Molina, Waseem Kaialy, Qiao Chen, Daniel Commandeur, Ali Nokhodchi
Spray-drying allows to modify the physicochemical/mechanical properties of particles along with their morphology. In the present study, L-leucine with varying concentrations (0.1, 0.5, 1, 5, and 10% w/v) were incorporated into lactose monohydrate solution for spray-drying to enhance the aerosolization performance of dry powder inhalers containing spray-dried lactose-leucine and salbutamol sulfate. The prepared spray-dried lactose-leucine carriers were analyzed using laser diffraction (particle size), differential scanning calorimetry (thermal behavior), scanning electron microscopy (morphology), powder X-ray diffraction (crystallinity), Fourier transform infrared spectroscopy (interaction at molecular level), and in vitro aerosolization performance (deposition)...
December 19, 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/29247741/investigations-on-the-mechanism-of-magnesium-stearate-to-modify-aerosol-performance-in-dry-powder-inhaled-formulations
#10
Martin Jetzer, Marcel Schneider, Bradley Morrical, Georgios Imanidis
The potential of the force control agent (FCA) magnesium stearate (MgSt) to enhance the aerosol performance of lactose-based dry powder inhaled (DPI) formulations was investigated in this study. The excipient blends were investigated with analytical techniques including time-of-flight secondary ion mass spectrometry (ToF-SIMS) and Single Particle Aerosol Mass Spectrometry (SPAMS) and particle size, morphology and surface properties were evaluated. Excipient-blends were manufactured either by high-shear or low-shear blending lactose carrier with different amounts of MgSt in the range from 0-10% (w/w)...
December 13, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29229103/effect-of-budesonide-formoterol-pressurized-metered-dose-inhaler-on-exacerbations-versus-formoterol-in-chronic-obstructive-pulmonary-disease-the-6-month-randomized-rise-revealing-the-impact-of-symbicort-in-reducing-exacerbations-in-copd-study
#11
Gary T Ferguson, Donald P Tashkin, Tor Skärby, Carin Jorup, Kristina Sandin, Michael Greenwood, Kristine Pemberton, Frank Trudo
BACKGROUND: Prevention of exacerbations is a primary goal for chronic obstructive pulmonary disease (COPD) therapy. This randomized, double-blind, double-dummy, parallel-group, multicenter study evaluated the effect of budesonide/formoterol pressurized metered-dose inhaler (pMDI) versus formoterol dry powder inhaler (DPI) on reducing COPD exacerbations. METHODS: 1219 patients aged ≥40 years with moderate-to-very-severe COPD (per lung function) and a history of ≥1 COPD exacerbation received budesonide/formoterol pMDI 320/9 μg twice daily (BID) during a 4-week run-in...
November 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29227727/a-randomized-clinical-trial-comparing-the-ellipta-and-handihaler-dry-powder-inhalers-in-patients-with-copd-inhaler-specific-attributes-and-overall-patient-preference
#12
Kathryn A Collison, Pinal Patel, Andrew F Preece, Richard H Stanford, Raj K Sharma, Gregory Feldman
This randomised, open-label, cross-over, placebo-containing inhaler study assessed patient preference indicators for ELLIPTA and HandiHaler dry powder inhalers in patients with COPD (NCT02786927; GSK identifier: 204983). The primary objective of this study was to assess patient preference between ELLIPTA and HandiHaler based on the number of steps needed to use the inhaler. Eligible patients ≥40 years of age with COPD were randomised 1:1 to receive their current COPD medication plus a placebo-containing ELLIPTA or HandiHaler inhaler once daily for 7 ± 2 days (treatment period 1); this was followed by a 7 ± 2-day placebo treatment with the alternative inhaler...
December 11, 2017: COPD
https://www.readbyqxmd.com/read/29223508/on-the-pharmacokinetics-of-two-inhaled-budesonide-formoterol-combinations-in-asthma-patients-using-modeling-approaches
#13
K Soulele, P Macheras, V Karalis
Dry powder inhalers containing the budesonide/formoterol combination have currently a well-established position among other inhaled products. Even though their efficacy mainly depends on the local concentrations of the drug they deliver within the lungs, their safety profile is directly related to their total systemic exposure. The aim of the present investigation was to explore the absorption and disposition kinetics of the budesonide/formoterol combination delivered via two different dry powder inhalers in asthma patients...
December 6, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29219321/sheta2-dry-powder-aerosols-for-tuberculosis-formulation-design-and-optimization-using-quality-by-design
#14
Mariam Ibrahim, Manolya Kukut Hatipoglu, Lucila Garcia-Contreras
Tuberculosis (TB) is a life threatening pulmonary infection caused by Mycobacterium tuberculosis (MTB). Current treatments are complex, lengthy and associated with severe side effects that decrease patient compliance and increase the probability of the emergence of drug resistant strains. Thus, more effective drugs with little to no side effects are needed to diversify the armamentarium against the global TB epidemic. SHetA2, an anticancer compound with null toxicity at doses much higher than the effective dose, was recently discovered to be active against MTB...
December 8, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29216805/a-review-on-recent-technologies-for-the-manufacture-of-pulmonary-drugs
#15
Gabriela Daisy Hadiwinoto, Philip Chi Lip Kwok, Richard Lakerveld
This review discusses recent developments in the manufacture of inhalable dry powder formulations. Pulmonary drugs have distinct advantages compared with other drug administration routes. However, requirements of drugs properties complicate the manufacture. Control over crystallization to make particles with the desired properties in a single step is often infeasible, which calls for micronization techniques. Although spray drying produces particles in the desired size range, a stable solid state may not be attainable...
January 2018: Therapeutic Delivery
https://www.readbyqxmd.com/read/29216744/dose-uniformity-of-budesonide-easyhaler%C3%A2-under-simulated-real-life-conditions-and-with-low-inspiration-flow-rates
#16
Jussi Haikarainen, Paula Rytilä, Sirkku Roos, Sirpa Metsärinne, Anita Happonen
Budesonide Easyhaler® multidose dry powder inhaler is approved for the treatment of asthma. Objectives were to determine the delivered dose (DD) uniformity of budesonide Easyhaler® in simulated real-world conditions and with different inspiration flow rates (IFRs). Three dose delivery studies were performed using 100, 200, and 400 µg/dose strengths of budesonide. Dose uniformity was assessed during in-use periods of 4-6 months after exposure to high temperature (30°C) and humidity (60% relative humidity) and after dropping and vibration testing...
January 1, 2017: Chronic Respiratory Disease
https://www.readbyqxmd.com/read/29212836/inhaler-technique-does-age-matter-a-systematic-review
#17
REVIEW
Sarah Barbara, Vicky Kritikos, Sinthia Bosnic-Anticevich
Poor inhaler technique and inferior asthma outcomes are evident in older adults. Reviews comparing metered dose inhaler (MDI) and dry powder inhaler (DPI) techniques across older adults and younger cohorts are scarce. This systematic review aimed to determine whether differences exist between such cohorts with regards to the number and type of MDI and DPI errors made. A systematic literature search was conducted in Embase, Medline and PubMed from July 1 to December 31, 2016. Studies were selected in accordance with preset inclusion criteria, relevant data were extracted, and quality was assessed with validated checklists...
December 31, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29160160/ideal-particle-sizes-for-inhaled-steroids-targeting-vocal-granulomas-preliminary-study-using-computational-fluid-dynamics
#18
Elizabeth L Perkins, Saikat Basu, Guilherme J M Garcia, Robert A Buckmire, Rupali N Shah, Julia S Kimbell
Objectives Vocal fold granulomas are benign lesions of the larynx commonly caused by gastroesophageal reflux, intubation, and phonotrauma. Current medical therapy includes inhaled corticosteroids to target inflammation that leads to granuloma formation. Particle sizes of commonly prescribed inhalers range over 1 to 4 µm. The study objective was to use computational fluid dynamics to investigate deposition patterns over a range of particle sizes of inhaled corticosteroids targeting the larynx and vocal fold granulomas...
November 1, 2017: Otolaryngology—Head and Neck Surgery
https://www.readbyqxmd.com/read/29158280/anti-pseudomonal-activity-of-phage-pev20-in-a-dry-powder-formulation-a-proof-of-principle-study-in-a-murine-lung-infection-model
#19
Rachel Yoon Kyung Chang, Ke Chen, Jiping Wang, Martin Wallin, Warwick Britton, Sandra Morales, Elizabeth Kutter, Jian Li, Hak-Kim Chan
Bacteriophage therapy is a promising alternative treatment to antibiotics as it has been documented to be efficacious against multi-drug resistant bacteria with minimal side effects. Several groups have demonstrated the efficacy of phage suspension in vivo to treat lung infections using intranasal delivery; however, phage dry powder administration to the lungs has not yet been explored. Powder formulations provide potential advantages over liquid formulation, including easy storage, transport and administration...
November 20, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29152321/impact-of-the-number-of-repeated-inhalations-and-patient-characteristics-on-the-residual-amount-of-inhaled-laninamivir-octanoate-hydrate-dry-powder-in-pediatric-patients-with-influenza
#20
Toshiki Murasaka, Kenji Ikemura, Tomoyuki Enokiya, Yuichi Muraki, Mayumi Ikemura, Koji Terada, Takuya Iwamoto, Masahiro Okuda
Background: A dry powder inhaled formulation is used for the anti-influenza drug laninamivir octanoate hydrate (laninamivir). Although two successive inhalations (puffs) are recommended to minimize residual amounts of active ingredients, previous reports suggest that pediatric patients with low peak inspiratory flow are unable to inhale the active ingredient adequately. In the present study, we prospectively investigated the appropriate number of repeated inhalations of laninamivir dry powder and factors influencing the residual amount of ingredients in pediatric patients with influenza...
2017: Journal of Pharmaceutical Health Care and Sciences
keyword
keyword
108963
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"